Background {#Sec1}
==========

*Mycoplasma pneumoniae* (MP) is a common pathogen that causes community-acquired pneumonia in children \[[@CR1]\]. MP infection is considered a self-limited disease. However, it has been verified that MP infection can progress into severe disease in some cases \[[@CR2]\]. Increasing numbers of refractory or severe *Mycoplasma pneumoniae* pneumonia (MPP) cases have been reported worldwide, especially in Asia \[[@CR2], [@CR3]\]. Previous studies have shown that refractory *Mycoplasma pneumoniae* pneumonia (RMPP) is associated with prolonged fever, high levels of C-reactive protein (CRP), airway hypersecretion and consolidation on chest imaging \[[@CR4], [@CR5]\]. It has been confirmed that the excessive immune response of the host plays an important role in the development of RMPP \[[@CR5], [@CR6]\]. However, whether different features of pathogens contribute to the development of RMPP remains unclear. Previous research confirmed that coinfection with viruses and bacteria led to more severe disease in children with RMPP \[[@CR7]\]. In addition, macrolide-resistant MP infection may also play an important role in the occurrence and development of RMPP \[[@CR8]\].

The purpose of this study was to investigate the impacts of viral coinfection and macrolide-resistant MP infection on hospitalized MPP patients, to identify the risk factors for these possible impacts, and then to build a model to predict a severe disease course.

Methods {#Sec2}
=======

Subjects and specimens {#Sec3}
----------------------

The study was performed from December 1, 2016, to May 31, 2019, at Shanghai Children's Medical Center (SCMC), a tertiary care hospital in Shanghai. Patients was enrolled according to the inclusion criteria: (1) patients with symptoms such as: fever, cough, wheezing; (2) physical examination revealed rales in the lungs; (3) imaging examination confirmed inflammation in the lungs. Patients with MPP were diagnosed according to the clinical practice guidelines for the management of community-acquired pneumonia in infants and children and the British Thoracic Society guidelines for the management of community-acquired pneumonia in children updated in 2011 \[[@CR9], [@CR10]\]. RMPP was defined as: (1) a sustained fever for 7 days or more and; (2) increasingly severe cough and infiltrates on chest radiographs despite the administration of appropriate macrolide antibiotics. MP was detected by FilmArray Respiratory Panel (FilmArray RP), a multiplex polymerase chain reaction (PCR) assay that detects 16 viruses, MP, *Bordetella pertussis (B. pertussis),* and *Chlamydophila pneumonia (C. pneumoniae)*. Children with congenital or secondary immunodeficiency were excluded.

Nasopharyngeal swabs (NPSs) or sputum specimens were collected from patients once they were admitted to our hospital and MP-IgM was tested at the same time. The medical records of each patient, including demographic data, clinical features, laboratory tests and radiological results, were obtained. The study was approved by the Institutional Review Board of Shanghai Children's Medical Center (SCMCIRB-K2017044), and written informed consent was obtained from the parents of each patient.

FilmArray RP v 1.7 testing {#Sec4}
--------------------------

The FilmArray Respiratory Panel v1.7 detects 19 pathogens: adenovirus (ADV); influenza A viruses H1, 2009H1, H3 (FluA-H1, FluA-2009H1, FluA-H3) and FluB; parainfluenza virus types 1 to 4 (Para 1--4); coronaviruses 229E, HKU1, OC43, and NL63 (Cov-HKU1, NL63, 229E, OC43); human metapneumovirus (hMPV); respiratory syncytial virus (RSV); human rhinovirus/enterovirus (Rhino/Entero); *C. pneumoniae*); *MP*; and *B. pertussis*. The FilmArray Respiratory Panel assay was performed according to the manufacturer's instructions. The principle of the assay has been previously described \[[@CR11]--[@CR13]\].

Detection of MP drug-resistant genes {#Sec5}
------------------------------------

Nasopharyngeal aspirates were collected at admission and assayed for MP DNA copy number using the QIAamp DNA MINI kit (QIAGEN, Germany). The sequence of the drug resistance locus was retrieved from GenBank, and primers were designed to amplify the drug resistance locus. The amplified product length was approximately 150 bp. The primer sequences were as follows: MP 1F: AACTATAACGGTCCTAAGGTAGCG, MP 2R: GCTCCTACCTATTCTCTACATGAT. Each reaction contained 0.125 l of EX tag HS enzyme, 2.5 l of dNTP, 2.5 l of 10\*EX tag buffer, 0.5 l of Primer F, 0.5 l of Primer R, 2 l of template DNA and ddH2O to achieve a final volume of 25 l. The cycling conditions were as follows: 94 °C for 5 min, followed by 35 cycles of 94 °C for 20 s, 55 °C for 30 s, and 72 °C for 30 s with a final extension step of 72 °C for 5 min. The DNA product was then sequenced by an external vendor (BGI, Shanghai, China), and the sequencing results were submitted to NCBI blast for analysis. The nucleotide at position 2063 was A for wild type but G for the mutant. The 23S rRNA domain V was amplified by nested PCR using a Veriti® 96-Well Thermal Cycler (Singapore). Finally, the DNA sequences were obtained (ABI, America).

Serological testing {#Sec6}
-------------------

To detect MP antibodies, commercially available IgM indirect immunofluorescence assays (IFA) were performed (Pneumoslide IgM, Vircell, S.L., Spain). Serological diagnosis was defined by the appearance of green fluorescence around the cell.

Statistical analysis {#Sec7}
--------------------

A *P* value\< 0.05 was considered statistically significant. Categorical variables are expressed as frequencies and percentages. The chi-square test was used to compare groups. Continuous variables are expressed as the means and standard deviations, and comparisons were made using Student's t-tests. Variables that had a *P* value\< 0.05 in the univariate logistic analysis were included in the multivariate logistic regression analysis. Multivariate analysis using stepwise forward selection was used to create a logistic proportional hazards model to determine the independent risk factors for ADV coinfection or drug-resistant MP infection. The inclusion criterion for the factors was a *P* \< 0.05. The sensitivity and specificity of the model were evaluated using receiver operating characteristic (ROC) curve analysis. Analyses were performed using SPSS v22.0.

To determine the optimal cut-off value for age for assessing the risk of viral coinfection, we applied a classification tree. This machine learning tree-based approach applied binary recursive partitioning for age. The recursion was completed when splitting no longer added value to the prediction of the risk of coinfection.

Results {#Sec8}
=======

Clinical characteristics of patients {#Sec9}
------------------------------------

A total of 107(10.63%,107/1007) patients diagnosed with MPP, aged 81 days to 14 years, were enrolled in our study between December 1, 2016, and May 31, 2019. Of these, 55 patients were male. MP-IgM of 83 patients were positive during the study period. The study design is illustrated in Fig. [1](#Fig1){ref-type="fig"}. There was no significant difference in gender. Fifty-six patients were diagnosed with RMPP. The general characteristics of all 107 patients are shown in Table [1](#Tab1){ref-type="table"}. Fig. 1Flow diagram illustrating the design of the present studyTable 1General characteristics of the patientsCharacteristicNo (%)Total107Age (y)4.268 ± 3.294Gender, No. (%) Male55(51.40) Female52(48.60)Underlying diseases, No. (%) None98(91.59) Congenital heart disease5(4.67) Congenital biliary atresia2(1.87) Other diseases2(1.87)Symptoms and signs Fever, No. (%)100(93.46) Duration of fever (d)7.690 ± 5.770 Cough, No. (%)107(100) Wheezing, No. (%)20(18.69) Duration of wheezing (d)0.00(0.00,5.00)RMPP, No. (%)56(52.34)Hypoxemia, No. (%)16(14.95)Mechanical ventilation, No. (%)7(6.54)Application of glucocorticoids, No. (%)60(56.07)Replacement of antibiotics, No. (%)19(17.76)7-day course of azithromycin, No. (%)42(39.25)Coinfection, No. (%)60(56.07)MP with A2063G mutation, No. (%)60(56.07)Prognosis after treatment, No. (%) Surviving105(98.13) Nonsurviving2(1.87)Data are No. (%) of patients, mean ± standard deviation (SD) or median (interquartile range)

Distribution and prevalence of pathogens {#Sec10}
----------------------------------------

Among the 107 patients, 60 patients were coinfected with viruses, including human rhinovirus/enterovirus, ADV, RSV, parainfluenza virus type 1, parainfluenza virus type 3, parainfluenza virus type 4, coronavirus OC43, coronavirus 229E, FluA and FluB. The overall coinfection rate was 56.07%. ADV was the most prevalent organism, accounting for 22.43% (24/107), followed by parainfluenza virus (13.08%,14/107) and human rhinovirus/enterovirus (11.21%, 12/107) (Fig. [2](#Fig2){ref-type="fig"}). Two or more pathogens were detected in 11 patients, and the rate of infection with multiple viruses was 10.28%. Coinfections were more likely to be found in younger patients. Three years old may be an optimal cut-off value to distinguish viral coinfection from MP single infection using the machine learning-based method, the classification tree. Fig. 2Pathogens detected by FilmArray RP

All patients enrolled in this study underwent A2063G and A2064G mutation gene tests with PCR. Sixty (60/107, 56.07%) patients were confirmed to have a gene mutation, all of which were A2063G mutations, the most prevalent mutation in Asian countries. Among the 60 patients infected with drug-resistant MP, 40 (40/60, 66.67%) progressed to RMPP. However, only 16 (16/47, 34.04%) children infected by drug-sensitive MP were diagnosed with RMPP.

Clinical characteristics of general MPP and RMPP {#Sec11}
------------------------------------------------

Fifty-six (56/107, 52.34%) patients were diagnosed with RMPP during our research period. A2063G mutation and coinfection with ADV were more commonly detected in the RMPP group (*P* = 0.001; *P* = 0.019). More patients with RMPP continued having a fever after receiving macrolide antibiotic treatment for 48 h (*P* \< 0.001), leading to a significantly longer duration of fever (*P* \< 0.001) and increasing the proportion of patients using glucocorticoids (*P* = 0.001). Although there were no significant differences in the leukocyte counts and CRP levels, the erythrocyte sedimentation rate (ESR) was higher in the RMPP group (*P* = 0.045). There were no remarkable differences in the total coinfection rate and single virus coinfection rate between the two groups, except for the patients with ADV coinfection (*P* = 0.019). ADV coinfection was more likely to be detected in patients with RMPP. With respect to the lung radiographs, more pulmonary consolidation was found in the patients with RMPP. In contrast, interstitial changes were likely to be discovered in general MPP (GMPP) (*P* = 0.02) (Table [2](#Tab2){ref-type="table"}). Table 2Clinical characteristics of GMPP and RMPPCharacteristicsGMPP (*n* = 51)RMPP (*n* = 56)*P* valueAge (y)3.679 ± 3.1934.805 ± 3.3220.077Gender (male/female)27/5128/560.847Clinical presentation Wheezing, No. (%)7(13.73)13(23.21)0.227 Hypoxemia, No. (%)4(7.84)12(21.43)0.060 Duration of fever (d)4.784 ± 2.83110.339 ± 6.473\< 0.001 Duration of wheezing (d)0.00(0.00,5.00)0.00(0.00,7.00)0.459 Extrapulmonary complications, No. (%)6(11.76)12(23.21)0.137Imaging features, No. (%) Consolidation, No. (%)22(43.14)37(66.07)0.02 Interstitial changes, No. (%)26(50.98)16(28.57)0.029Laboratory detection White blood cell count (\*10^9^/L)9.583 ± 3.3488.420 ± 3.5300.084 Lymphocyte percentage (%)37.291 ± 14.81732.352 ± 14.6900.088 C-reactive protein (mg/l)12.00(8.00,25.00)11.00(5.00,25.75)0.664 ESR (mm/h)29.11 ± 19.93537.88 ± 22.4120.045 Coinfection, No. (%)28(54.90)32(57.14)0.847 Coinfection with adenovirus, No. (%)6(11.76)18(32.14)0.019 A2063G mutation, No. (%)20(39.22)40(71.43)0.001Treatment No fever within 48 h after application of macrolides, No. (%)6(11.76)50(89.29)\< 0.001 Application of glucocorticoids, No. (%)24(47.06)44(78.57)0.001 Mechanical ventilation, No. (%)4(7.84)3(5.36)0.707Data are No. (%) of patients, mean ± standard deviation (SD) or median (interquartile range)Abbreviation: General *Mycoplasma pneumoniae* pneumonia (GMPP); refractory *Mycoplasma pneumoniae* pneumonia (RMPP)

Predictors of adenovirus coinfection or drug-resistant MP infection {#Sec12}
-------------------------------------------------------------------

As mentioned above, more children coinfected with ADV or infected with drug-resistant MP were found in the RMPP group than in the GMPP group. It is important to investigate the risk factors for ADV coinfection or macrolide-resistant MP infection. During the study period, 24 (24/107, 22.43%) patients were coinfected with ADV, which made the course of the disease more severe. Nine (9/24, 37.5%) patients who developed extrapulmonary complications were coinfected with ADV, whereas only 10 (10/83, 12.05%) children were diagnosed with extrapulmonary complications in the non-ADV group (*P* = 0.012). Wheezing and lung consolidation were more likely to occur in children with ADV coinfection than in those without (*P* = 0.002; *P* = 0.010). Furthermore, the duration of fever in ADV-coinfected patients was much longer than in the other patients (*P* = 0.007) (Table [3](#Tab3){ref-type="table"}). Table 3Risk factors for MPP with adenovirus coinfectionCharacteristicsWith adenovirus coinfection (*n* = 24)Without adenovirus coinfection (*n* = 83)*P* valueAge (y)3.362 ± 2.5904.531 ± 3.4400.078Gender (male/female)13/1142/410.819Clinical presentation Wheezing, No. (%)10(41.67)10(12.05)0.002 Hypoxemia, No. (%)6(25.00)10(12.05)0.189 Extrapulmonary complications, No. (%)9(37.50)10(12.05)0.012 Duration of fever (d)12.083 ± 9.3436.422 ± 3.3570.007 Duration of wheezing (d)0.00(0.00,8.00)0.00(0.00,5.00)0.570 Fever longer than 7 days, No. (%)20(83.33)36(43.37)0.001Imaging features Consolidation, No. (%)19(79.17)40(48.19)0.010 Interstitial changes, No. (%)5(20.83)37(44.58)0.056Laboratory tests White blood cell count (\*10^9^/L)9.003 ± 3.4878.966 ± 3.4960.964 Lymphocyte percentage (%)36.488 ± 14.27434.153 ± 15.1060.491 C-reactive protein (mg/l)10.00(4.00,25.00)12.00(7.25,25.00)0.997 A2063G mutation, No. (%)9(37.50)51(61.45)0.060Treatment No fever within 48 h after application of macrolides, No. (%)5(20.83)26(31.33)0.445 Application of glucocorticoids, No. (%)17(70.83)51(61.45)0.476 Mechanical ventilation, No. (%)1(4.17)6(7.23)1Data are No. (%) of patients, mean ± standard deviation (SD) or median (interquartile range)

To identify drug-resistant MP infection, mutant gene detection was carried out. The total positive rate was 56.07%. The mutation rate was 71.43% in RMPP patients, which was significantly higher than that in the GMPP group (*P* = 0.001) (Table [2](#Tab2){ref-type="table"}). More patients with prolonged fever duration after the appropriate administration of macrolides for 48 h were in the group infected by drug-resistant MP than in the group not infected with drug-resistant MP (*P* = 0.002) (Table [4](#Tab4){ref-type="table"}). In addition, a fever duration longer than 7 days had a strong relationship with drug-resistant MP infection according to multivariable logistic regression (OR = 3.500, 95% CI = 1.310--9.353, *P* = 0.012). Table 4Risk factors for MPP with A2063G mutationCharacteristicsWithout A2063G mutation (*n* = 47)With A2063G mutation (*n* = 60)*P* valueAge (y)3.792 ± 3.5374.642 ± 3.0690.187Gender (male/female)23(58.97)32(53.33)0.699Clinical presentation Wheezing, No. (%)10(25.64)10(16.67)0.621 Hypoxemia, No. (%)8(20.51)8(13.33)0.599 Extrapulmonary complications, No. (%)9(23.08)10(16.67)0.802 Duration of fever (d)7.234 ± 6.3568.050 ± 5.2930.470 Duration of wheezing (d)0.00(0.00,6.50)0.00(0.00,5.00)0.499 Fever longer than 7 days, No. (%)16(41.03)35(56.33)0.019Imaging features, No. (%) Consolidation, No. (%)30(76.92)29(48.33)0.122 Interstitial changes, No. (%)16(41.03)26(43.33)0.425Laboratory tests, No. (%) White blood cell count (\*10^9^/L)9.274 ± 3.1798.740 ± 3.7010.433 Lymphocyte percentage (%)35.023 ± 15.92234.410 ± 14.1420.834 C-reactive protein (mg/l)13.00(8.00,29.00)11.00(4.50,22.00)0.107 ESR (mm/h)29.950 ± 21.99536.620 ± 21.1020.136Treatment No fever within 48 h after application of macrolides, No. (%)21(53.85)10(16.67)0.002 Application of glucocorticoids, No. (%)24(61.54)44(73.33)0.026 Mechanical ventilation, No. (%)4(10.26)3(5.00)0.697Data are No. (%) of patients, mean ± standard deviation (SD) or median (interquartile range)

Multivariable logistic regression was further carried out to verify the associations between the variables and ADV coinfection. Patients with symptoms of wheezing (X~1~) (OR = 5.559, 95% CI = 1.726--17.901, *P* = 0.004), consolidation on chest X-ray (X~2~) (OR = 4.290, 95% CI = 1.305--14.106, *P* = 0.016) and extrapulmonary complications (X~3~) (OR = 4.225, 95% CI = 1.331--13.603, *P* = 0.015) all had a higher risk of ADV coinfection than their counterparts (Table [5](#Tab5){ref-type="table"}). Therefore, based on logistic regression, a prediction model including wheezing, lung consolidation and extrapulmonary complications was established: Logit(P) = (− 2.931) + 1.715X~1~ + 1.456X~2~ + 1.488X~3~. The predictive values of the individual risk factors and the prediction model were assessed by ROC curve analysis, which showed that the model had a high level of diagnostic accuracy, with an AUC of 0.795 (95% CI 0.679--0.893, *P* \< 0.001). Additionally, wheezing, lung consolidation and extrapulmonary complications had some predictive value separately (Fig. [3](#Fig3){ref-type="fig"}). Table 5Analysis of risk factors related to adenovirus coinfectionVariablesOR (95%)*P* valueWheezing5.559(1.726--17.901)0.004Lung consolidation4.290(1.305--14.106)0.016Extrapulmonary complications4.225(1.331--13.603)0.015Fig. 3Receiver operating characteristic (ROC) analysis showing the power of the risk factors and prediction model for the prediction of adenovirus coinfection. The area under the ROC curve (AUC) of the prediction model for the prediction of adenovirus coinfection was 0.795

Discussion {#Sec13}
==========

MP is a common pathogen that causes community-acquired pneumonia in children \[[@CR1]\]. The proportion of pneumonia caused by MP in different studies ranged from 20 to 40% \[[@CR14]\]. In the present study, the MP infection rate was 10.63%. Besides, the MP infection rate may increase with age according to Li's research \[[@CR12]\]. MP-IgM may not be detectable in the very early stage of the disease, which may explain why only 83 patients were MP-IgM positive in the present study. This result suggests that combining MP-IgM and RT-PCR could increase the diagnostic accuracy of mycoplasma infection in children, similar to the findings of the study by Biljana Medjo's \[[@CR15]\]. In general, viral coinfection rates in children with MPP ranged from 10 to 30% \[[@CR16]--[@CR20]\]. In the present study, 56.07% of patients were coinfected with at least one type of virus, which was higher than the proportions reported in other studies, possibly because of different climates and races. Additionally, the sensitivity and accuracy of the FilmArray respiratory pathogen panel contributed to a higher positive rate as well. Viral coinfections were more likely to be found in relatively younger children, especially those under 3 years old, which is similar to the results of Zhang's research \[[@CR7]\].

It should be noted that ADV coinfection and drug-resistant MP infection were more common in the RMPP group than in the GMPP group. A previous study showed that compared with RMPP children without coinfections, those who were coinfected with viruses and bacteria had more severe disease \[[@CR20]\]. Thus, respiratory viral infection may lead to the development of RMPP, and coinfection might result in further progression of the disease. However, in this study, no remarkable differences in clinical characteristics were observed between patients who were and were not coinfected, except for in those with ADV coinfections.

ADV infection may cause severe disease necessitating ICU admission and mechanical ventilation \[[@CR21]\]. The severity of pneumonia with ADV coinfection is significantly related to viral load and serotypes, and children with ADV genotype 7 develop severe pneumonia more frequently than those with other genotypes \[[@CR22]\]. However, the effect of ADV coinfection on MPP in children remains unclear. According to the present results, this is the first study to report that ADV coinfection led to more severe disease severity in children with MPP and increased the proportion of children with RMPP. Furthermore, a prediction model including wheezing, lung consolidation and extrapulmonary complications was established to predict ADV coinfection in children with MPP. This prediction model can help clinicians identify a severe disease course of MPP early, which is beneficial for the precise selection of medications.

Drug resistance is another inevitable factor contributing to the development of RMPP \[[@CR8]\]. Mutations at position 2063 or 2064 domain V in the 23S rRNA gene are considered to be related to macrolide resistance \[[@CR22], [@CR23]\]. The mutation rate in this study was 56.07%, of which were all A2063G mutations. The rate of drug-resistant MP was lower than those reported in other studies in China, where the rates range from almost 70 to 90% \[[@CR21], [@CR22], [@CR24]\]. This is the because point mutations in drug-resistance genes were detected by PCR in this study, while drug sensitivity tests were chosen by other researchers. In addition, racial differences also play an important role in drug-resistant MP infection. Macrolide resistance is less common in the United States and European countries, where the macrolide-resistant MP prevalence is below 30% \[[@CR23], [@CR25], [@CR26]\]. A relatively high mutation rate in China is probably related to immoderate exposure to macrolides, since they are widely used for the treatment of respiratory infections in outpatients, especially in children. Therefore, alternative medicines are urgently needed.

A study from Japan reported that the macrolide-resistance rate decreased by 59.3% in 2014 and 43.6% in 2015 from the highest macrolide-resistance rate of 81.6% in 2012 \[[@CR27]\]. Guidelines published by the Japan Society of Pediatric Pulmonology/Japanese Society for Pediatric Infectious Diseases recommend tosufloxacin, which was approved for pediatric use in Japan in 2010, as a second-line drug when patients have a fever for 2--3 days after the administration of macrolides \[[@CR28]\]. Hence, the decrease in the drug-resistance rate during this period may be attributed to the decrease in the use of oral macrolides. In children with drug-resistant MPP, tetracyclines (doxycycline, minocycline) have shown excellent efficacy \[[@CR29]--[@CR31]\]. Tetracyclines are well known for causing adverse reactions, including gastrointestinal disturbances, esophagitis, photosensitivity, and tooth discoloration \[[@CR32]\]. Because of these adverse reactions, tetracyclines are contraindicated in pregnant women and children under 8 years old. However, previous studies showed that short cycles and limited courses of treatment (fewer than 6 courses, 6 days per course) caused insignificant tooth discoloration in children under 5 years old \[[@CR33]\]. This study showed that drug-resistant MP infection contributes to the development of RMPP. On the other hand, high MP-DNA copy numbers might indicate a severe disease course in MPP children. A previous study showed that a reduced MP-DNA copy number in the sputum was well correlated with patients' clinical symptoms and the therapeutic efficacy of antibiotics \[[@CR34]\]. Studies have shown that levofloxacin and minocycline therapy in patients who are nonresponsive to macrolides may reduce their fever duration and result in a more rapid decrease in the sputum MP-DNA copy number \[[@CR35], [@CR36]\]. Despite the efficacy of fluoroquinolones, clinicians should be aware of the adverse reactions (musculoskeletal adverse events), and the usage of fluoroquinolones should be based on in vitro activity and disease severity in children with MPP.

As mentioned above, it was found that patients infected with drug-resistant MP have a longer fever duration, and more of them maintained a fever for more than 2 days after the appropriate application of macrolides. Hence, switching antibiotics should be considered when a patient still has a fever after the administration of macrolides for 2 days. A long fever duration of 7 days may strongly suggest infection with drug-resistant MP, which indicates that changing to a more effective antibiotic is urgently required. In our department, the policy for changing antibiotics is as follows: 1. if the patient is infected with MP only or coinfected with virus, based on laboratory tests and clinical symptoms, antibiotics are not changed until the first 5-day course is finished, with the prerequisite that the patient is not seriously ill; 2. if the patient has coinfection with other bacteria, we usually combine penicillin or cephalosporin with a macrolide. For patients with drug-resistant MP infections or whose condition worsens (sustained fever, deterioration on lung imaging or worsening clinical symptoms), minocycline is the first consideration for patients older than 8 years, while for those younger than 8 years, levofloxacin is applied only in case of severe pneumonia.

Nevertheless, this study has several limitations. First, this study was performed at a single center, and the distribution of pathogens was greatly influenced by the region and climate. In addition, the sample size was relatively small. Furthermore, the immune conditions of the patients were not investigated in our research, and immunity may affect the severity of MPP.

Conclusions {#Sec14}
===========

The occurrence of RMPP is associated with ADV coinfection and drug-resistant MP infection. A prediction model combining wheezing, extrapulmonary complications and lung consolidation can be used to predict ADV coinfection in children with MPP. Viral coinfections are more common in MPP patients under 3 years old. Macrolide-resistant MP infection should be taken into consideration when a patient continues to have a fever after the administration of appropriate macrolide antibiotics for 2 days. A 7-day fever duration despite the use of macrolide antibiotics strongly suggests that the patient is infected by drug-resistant MP, and a timely switch to another effective antibiotic should be considered after the potential adverse reactions to the medicine and severity of disease are evaluated.
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